Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.5% – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price traded down 6.5% during trading on Thursday . The stock traded as low as $9.52 and last traded at $10.16. 24,316,392 shares traded hands during trading, a decline of 4% from the average session volume of 25,259,420 shares. The stock had previously closed at $10.87.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.

Recursion Pharmaceuticals Trading Down 10.3 %

The company’s fifty day moving average price is $7.56 and its two-hundred day moving average price is $7.02. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $3.63 billion, a P/E ratio of -6.07 and a beta of 0.86.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock worth $229,908,000 after purchasing an additional 9,737,196 shares during the last quarter. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the last quarter. Softbank Group CORP. bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $99,152,000. State Street Corp grew its holdings in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after acquiring an additional 4,120,685 shares during the last quarter. Finally, Novo Holdings A S bought a new stake in Recursion Pharmaceuticals during the 4th quarter worth about $68,375,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.